Here are four insights:
1. The preclinical study revealed the growth factor successfully encourages bone formation in a phylogenetically advanced spine model.
2. The rhNELL-1 growth factor did not cause inflammation and was well tolerated.
3. Bone Biologics plans to launch a pivotal animal study in mid-2018.
4. The company’s rhNELL-1 program is set for human trials in 2019.
More articles on biologics:
HSS’ Dr. Christopher Mendias earns $800k grant for stem cell research — 5 notes
Denver Bronco Derek Wolfe to undergo stem cell treatment after diagnosis from Dr. Robert Watkins — 3 things to know
How do muscle stem cells react to injury and aging? 6 insights
